Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET
**Dosage and Administration:** The usual dose for adults: 10mg tablet once daily preferably at night on retiring.
ORAL
Medical Information
**Indication(s):** For prophylaxis of migraine, peripheral venous insufficiency and occlusive arterial disease.
**Contraindication(s):** 1. Patients known to be hypersensitive to this drug. 2. There is, as yet, no evidence of embryotoxic effects of Flunarizine in experimental animals. Nevertheless, the anticipated therapeutic benefits should be weighed against potential hazards before administering the compound during pregnancy.
N07CA03
flunarizine
Manufacturer Information
YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD
Y S P INDUSTRIES (M) SDN BHD
Active Ingredients
Documents
Package Inserts
Forknow Tablet PI approved on 8 Jul 2022.pdf
Approved: July 8, 2022